Zoetis Inc. $ZTS Shares Purchased by Capital Research Global Investors

Capital Research Global Investors increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,429,149 shares of the company’s stock after purchasing an additional 6,503 shares during the quarter. Capital Research Global Investors’ holdings in Zoetis were worth $179,816,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. RFG Advisory LLC increased its position in Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after purchasing an additional 80 shares in the last quarter. YANKCOM Partnership increased its position in Zoetis by 3.5% during the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after purchasing an additional 81 shares in the last quarter. Beese Fulmer Investment Management Inc. increased its position in Zoetis by 2.4% during the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after purchasing an additional 85 shares in the last quarter. Quest 10 Wealth Builders Inc. increased its position in Zoetis by 4.7% during the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after purchasing an additional 86 shares in the last quarter. Finally, Financial Engines Advisors L.L.C. increased its position in Zoetis by 4.4% during the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after purchasing an additional 87 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In related news, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Frank A. Damelio purchased 6,650 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by corporate insiders.

Zoetis Stock Down 0.8%

Shares of NYSE:ZTS opened at $78.80 on Tuesday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $169.50. The company has a 50 day moving average of $99.76 and a two-hundred day moving average of $115.24. The company has a market capitalization of $33.03 billion, a price-to-earnings ratio of 13.07, a price-to-earnings-growth ratio of 1.24 and a beta of 0.75.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the business posted $1.48 EPS. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, analysts forecast that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Analyst Ratings Changes

A number of analysts recently issued reports on ZTS shares. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Citigroup lowered their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Finally, Bank of America increased their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Zoetis currently has a consensus rating of “Hold” and a consensus price target of $133.92.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis received UK approval for Lenivia (izenivetmab), a long-acting osteoarthritis pain therapy for dogs, which could support future product sales and help offset some legal-related negativity. Zoetis (ZTS) Receives UK Approval for Long-Acting Osteoarthritis Pain Therapy Lenivia
• Neutral Sentiment: Multiple law firms, including Rosen Law Firm, Levi & Korsinsky, Glancy Prongay Wolke & Rotter, Robbins Geller, the Schall Law Firm, Bronstein Gewirtz & Grossman, and DJS Law Group, issued repeated reminders about the pending securities class action and the July 27 lead-plaintiff deadline. ROSEN, A LONGSTANDING LAW FIRM, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS
• Negative Sentiment: The class-action filings alleging securities-law violations and investor losses may increase legal costs, create headline risk, and keep pressure on Zoetis shares until more clarity emerges. Zoetis Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – ZTS

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.